Crescita Announces Definitive Agreement to Be Acquired by ClinActiv Holdings in an All-Cash Transaction at a Significant Premium

Core Viewpoint - Crescita Therapeutics Inc. has entered into a definitive agreement to be acquired by ClinActiv Holdings Inc. in an all-cash transaction at a significant premium, with a target purchase price of $0.80 per share, representing a 74% premium over the five-day volume weighted average price prior to the announcement [1][2]. Transaction Details - The purchase price of $0.80 per share is subject to adjustments based on the company's net working capital at closing, with a minimum price of $0.75 per share [1]. - The transaction will be executed through a court-approved statutory plan of arrangement and requires approval from at least two-thirds of the votes cast by shareholders [7]. - The expected closing of the transaction is in the second quarter of 2026, after which Crescita's shares will be delisted from the TSX [8]. Shareholder Support - Significant shareholders, including senior management and directors holding approximately 33% of outstanding shares, have signed agreements to vote in favor of the arrangement [3]. - The Board of Directors has unanimously recommended that shareholders vote for the arrangement after evaluating strategic alternatives [6]. Fairness Opinion - Bloom Burton Securities Inc. provided a fairness opinion stating that the purchase price is fair to Crescita's shareholders from a financial perspective [4]. Strategic Intent - ClinActiv aims to build a global dermatology platform through this acquisition, leveraging Crescita's integrated platform and expertise in dermatology [5]. - The transaction is seen as a strategic move to enhance Crescita's growth potential through access to ClinActiv's commercial networks and product portfolios [5]. Post-Closing Reorganization - Following the closing, a reorganization will occur where ClinActiv retains ownership of Crescita's commercial skincare and contract manufacturing business, while the management group will acquire the remaining business [10]. - The Board has concluded that this reorganization provides a net benefit to Crescita's shareholders [10].